IgGenix has reported that the initial patient has been dosed in its Phase 1 trial, named "ACCELERATE Peanut," which is testing IGNX001 for peanut allergies.

Ravulizumab is composed of two types of polypeptide chains, light and heavy chains, which are typical of monoclonal antibodies.

Innovent has revealed that its Phase 2 clinical trial of Picankibart (IBI112) in Chinese patients with ulcerative colitis has met its primary goal.

Structurally, mylotarg is characterized by its humanized IgG4 backbone, which contributes to its stability and reduced immunogenicity.

Alnylam has filed a regulatory application with the European Medicines Agency for Vutrisiran aimed at treating ATTR amyloidosis with cardiomyopathy.

SciRhom GmbH has announced the initiation of participant dosing in their first clinical trial for the advanced development program SR-878.

UroGen Pharma announced the acceptance of its NDA by the U.S. FDA for the investigational product UGN-102 (mitomycin) intended for intravesical administration.

Adicet Bio has received FDA approval for an IND amendment to study ADI-001 in idiopathic inflammatory myopathy and Stiff Person Syndrome.

ViiV Healthcare reports over 99% effectiveness for Apretude (Cabotegravir Long-Acting) in real-world studies.

Sanofi has partnered with Orano Med, a branch of the Orano Group that leads in the advancement of targeted alpha therapies for cancer treatment.

uniQure N.V. has announced that the initial participant has received a dose in the Phase I/II clinical study of AMT-162.

The application of AI in drug discovery can reduce the development timeline and increase the success rate of new drugs from 12% to 14%.